Posts Tagged ‘ Merck ’

Is Your Doctor Getting Cash from Big Pharma? Find Out

October 20th, 2010. By AbiK

It’s been a good year for Dr. Firhaad Ismail. Indeed! Financially speaking, that is. See, according to the info over at ProPublica, in their Dollars for Docs report, Dr. Ismail took in no less than $303,558 from big pharmaceutical companies GlaxoSmithKline (GSK…the folks who brought you Avandia and Paxil), Eli LIlly, and Merck.

Now, Dr. Ismail is just one of 384 doctors nationwide who’ve received payment from big pharma. Ismail is based in Vegas (clearly, if ProPublica’s involved, what goes on in Vegas is not staying in Vegas) and his specialty is Endocrinology and Metabolism. And he appears to do a fair amount of consulting on the topic. On big pharma’s dime.

Dr. Ismail may be the best damn doctor there is in his specialty. I don’t know. But what I do know is that the ProPublica report indicates that Dr. Ismail received a total of $209,400 from GSK alone. Recall what area of practice Dr. Ismail is in…Endocrinology. What does Endocrinology deal with? Well, diabetes for one. And last I checked, Avandia is a type 2 diabetes drug made by GSK.

I’m just putting on the table what’s already out there. I’m not saying there’s any unsavory relationship here…but I the jaded skeptic in me does raise a little eyebrow…

Needless to say, I’ve been checking out my own doctors over at ProPublica.com. You can, too. Just hop over to Dollars for Docs and do a search for your doctor’s name, by state. You can also find a full list there of all the doctors nationwide.

Let us know what you find…and if you think doctors receiving funds from big pharma presents a conflict of interest.

Tags: Dollars for Docs, Dr. Firhaad Ismail, Eli Lilly, GSK, Merck, ProPublica
Posted in Drugs/Medical | 5290No Comments »2010-10-20+12%3A25%3A27AbiK

Worth a Read – Fosamax Article in More Magazine

June 7th, 2010. By AbiK

Finally got to catch up on some reading this weekend and found myself flipping through the latest More magazine. The one with Sharon Stone on the cover—looking great at 52 (not to take away from Stone’s smarts or her three adopted children, but my response to any “hot body over 40″ (or 50) press is, ok, but has she gone through childbirth?—and sans plastic surgery? if so, then let’s talk; otherwise, get real.) But I digress.

What I really want to talk about is the article by Katharine Davis Fishman that’s a bit further back in the June issue. Page 119, to be exact. Title: Boning Up on Bone Drugs. It’s about Fosamax and femur fractures.

And it’s worth a read—particularly if you’re a woman, of a certain age—or nearing that age, or one who’s been taking bisphosphonates—either as a result of a diagnosis of osteoporosis, or as a preventative measure against such bone degeneration.

Fishman presents her own incredible journey through osteoporosis, Fosamax prescriptions, and then a seemingly out-of-the-blue femur fracture after tripping on a rug. Her description of the incident is enough to bring on a palpable wince in the reader. Heck, I got up mid-article and popped a Caltrate D.

The part of the article I found most interesting was the delineation of what Fosamax (and others of its ilk like Actonel, Didronel, Boniva, Aredia, Reclast, Zometa, Skelid) was initially intended to treat, and where it’s evolved to. Bisphosphonates are prescribed to help prevent the breakdown of bone—to help prevent hip fractures—which according to Fishman’s article have a harrowing statistic associated with them: Around 24 percent of elderly men and women who suffer a hip fracture die within a year of the fracture; another quarter wind up incapacitated in nursing homes; and the remainder typically never walk “right” again.

With that kind of prognosis, if I hear the word “osteoporosis” uttered in any examination room I’m in, I’m asking for a Fosamax scrip right then and there.

But wait a minute—that’s the problem. Apparently, Fosamax has been prescribed more and more as a preventative measure—it was approved for such in 1997, two years after its Read the rest of this entry »

Tags: femur fracture, Fishman, Fosamax, Fosamax femur fracture, Merck, More
Posted in Drugs/Medical | 38902 Comments »2010-06-07+17%3A22%3A49AbiK

Musing about Merck, Zetia and Gardasil

November 15th, 2009. By AbiK

gardasil Musing about Merck, Zetia and Gardasil So you caught the news recently that Merck’s Gardasil was approved by the FDA for use in boys ages 9 to 26. No one really expects much from this news—ie, doctors aren’t expected to be offering it to their male patients (or their parents as the case may be). But I find it interesting none the less.

First, the background…Gardasil is the vaccine that’s supposed immunize young girls (ages 9 – 26) from the HPV virus—aka, human papillomavirus, the sexually transmitted one that can lead to cervical cancer. There’s a lot of heated debate on Gardasil in girls–we’ve blogged on it as well–and the New York Times recently reported that in order to be effectively immunized with Gardasil, it requires a series of three injections, each costing $130 (translation, around $400; translation, it ain’t cheap).

But now let’s just take a look at that NYT report again. I read on through the whole article…la Read the rest of this entry »

Tags: Gardasil, Merck, Niaspan, Vytorin, Zetia
Posted in Drugs/Medical | 1890No Comments »2009-11-15+14%3A58%3A11AbiK

Merck in the Middle of Statin Drug Soap Opera

November 9th, 2009. By AbiK

dramamug Merck in the Middle of Statin Drug Soap Opera The latest flurry of statin drug-related news could substitute for your afternoon t.v. soap fix—except there’s a very real-life drama being played out. It’s full of intrigue and false promises. Who knew that the anti-cholesterol drug market could offer so much, and yet so little at the same time?

Here’s the topline history to get you up to speed—just in case you’ve missed the last couple of months’ news on drugs like Vytorin, Zetia and Lipitor…

Zetia + Simvastatin (aka Zocor) = Vytorin

â†“

Vytorin + Zetia = Class Action Settlement

â†“

Zetia + Atorvastatin (aka Lipitor) = Refused by FDA = Bad News for Merck

â†“

Vytorin + Arbiter 6 Study (due 11/16) = Expected Bad News for Merck

â†“

Niaspan + Arbiter 6 Study = Expected Good News for Abbott Labs

So what’s the deal with this Arbiter 6 thing? It’s the clinical study that was conducted—and whose results are hotly anticipated at the American Heart Association (AHA) annual scientific meeting in Orlando on November 16th—to review the efficacy of cholesterol drugs Read the rest of this entry »

Tags: Arbiter 6, Merck, statins, Vytorin, Zetia
Posted in Drugs/Medical | 1784No Comments »2009-11-09+15%3A00%3A35AbiK

Vytorin Zetia Settlement…What’s in it for You?

November 6th, 2009. By AbiK

LawyersAndSettlements.com reported a while ago (Aug. 5^th precisely) about the proposed class action settlement in the Vytorin-Zetia case against Merck and Schering-Plough.

At the heart of this case are claims that Vytorin and Zetia were marketed as being more effective than other anti-cholesteral drugs on the market (namely, those drugs in the class known as statins)—and that Vytorin and Zetia were sold at higher prices even though there wasn’t really evidence that they were more effective than less-expensive anti-cholesterol drugs.

For consumers—aka the “Consumer Class” of the Vytorin/Zetia settlement, it means that if you were taking either of these drugs and either paid or were obligated to pay for them between November 1, 2002 and September 17, 2009, you may be eligible to participate in this settlement. Translation: you may be able to get some money back on your purchases as a result of this settlement.

How much money?—it’s the number one question we always get about settlements. Well, as Read the rest of this entry »

Tags: Cholesterol, Merck, Vytorin, Zetia
Posted in Drugs/Medical, Settlement | 177232 Comments »2009-11-06+15%3A17%3A20AbiK